Tag: BioVAT-HF

Repairon Announces Completion of Dose-Finding Part of BioVAT-HF Phase 1/2 Trial in Advanced Heart Failure

Feasibility and safety demonstrated in patients with advanced heart failure Safe maximal dose for continuation into Phase 2 (Proof-of-Concept) identified Proof for successful heart remuscularization obtained Interim data on 15 patients with 800 million cells dose expected in Q2 2024 GÖTTINGEN, Germany, April 04, 2023 (GLOBE NEWSWIRE) — Repairon, a […]